Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 2/2020

01-02-2020 | Bevacizumab | Original Paper

Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity

Authors: Amir Eftekhari Milani, Narges Hassanpoor, Mohammadreza Mousavi Mirkala, Arash Taheri, Ali Golizade, Mohamad Reza Niyousha

Published in: International Ophthalmology | Issue 2/2020

Login to get access

Abstract

Purpose

To compare type I retinopathy of prematurity (ROP) with aggressive posterior retinopathy of prematurity (AP-ROP) regarding risk factors, complications and treatment outcomes.

Methods

A prospective cohort approach was applied on premature newborns diagnosed as type I ROP and AP-ROP. An intravitreal injection of bevacizumab (Avastin®) was given to each patient. Demographic features such as gestational age, birth weight, age at the initial injection, involved eye, treatment response, relapses and need to extra interventions were compared.

Results

Seventy-seven patients underwent an initial intravitreal injection of bevacizumab (IVB), and 108 eyes were type I ROP and 30 eyes were AP-ROP. There was no significant difference in birth weight and gestational age between two groups. ROP relapsed in eight eyes of four patients with AP-ROP (26.6%), of which six eyes of three patients received re-injection of bevacizumab, and two eyes of one patient underwent a laser treatment. Recurrence occurred in two eyes of one patient with type I ROP (1.8%), which were treated by laser.

Conclusion

Bilateral eye involvement, relapse and retreatment (IVB, laser and surgical intervention) are more frequent in AP-ROP than type I ROP even when treated with intravitreal bevacizumab injection.
Literature
1.
Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML et al (2013) Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 33(2):329–338CrossRef
2.
Terry TL (1944) Retrolental fibroplasia in the premature infant: V. Further studies on fibroplastic overgrowth of the persistent tunica vasculosa lentis. Trans Am Ophthalmol Soc. 42:383–396PubMedPubMedCentral
3.
Mutlu FM, Sarici SU (2013) Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 6(2):228–236PubMedPubMedCentral
4.
Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol (Chicago, Ill 1960) 121(12):1684–1694CrossRef
5.
Soejima N, Takagi I, Takashima Y (1976) Clinical studies on retinopathy of prematurity, severe and rapidly progressive type. Folia Ophthalmol Jpn 27(1):155–161
6.
Aaberg T, Ben-Sira I, Charles S, Clarkson J, Cohen BZ, Flynn J, Foos R, Garner A, Hirose T, Koerner F, Machemer R (1987) An international classification of retinopathy of prematurity. II. The classification of retinal detachment. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. Arch Ophthalmol (Chicago, Ill 1960) 105(7):906–912CrossRef
7.
8.
Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84(2):77–82CrossRef
9.
Feng J, Qian J, Jiang Y et al (2017) Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China. Ophthalmology 124(3):408–409CrossRef
10.
Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 35(4):675–680CrossRef
11.
Erol MK, Coban DT, Sari ES et al (2015) Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol 78(6):340–343CrossRef
12.
Khodabande A, Niyousha MR, Roohipoor R (2016) A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity. J AAPOS 20:490–492CrossRef
13.
Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ (2005) Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 115(4):990–996CrossRef
14.
Woo SJ, Park KH, Ahn J et al (2011) A co-twin study of the relative effect of birth weight and gestational age on retinopathy of prematurity. Eye (London) 25(11):1478–1483CrossRef
15.
Dhaliwal CA, Fleck BW, Wright E, Graham C, McIntosh N (2009) Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed 94(3):F193–F195CrossRef
16.
Sanghi G, Dogra MR, Das P, Vinekar A, Gupta A, Dutta S (2009) Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment. Retina 29:1335–1339CrossRef
17.
Nicoară SD, Ştefănuţ AC, Nascutzy C, Zaharie GC, Toader LE, Drugan TC (2016) Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis. Med Sci Monit 22:1192–1209CrossRef
18.
Li Xiu-Juan, Yang Xiao-Peng, Sun Shuang, Lyu Xiao-Bei, Jia Heng (2016) Intravitreal ranibizumab for aggressive posterior retinopathy of prematurity. Chin Med J (Engl) 129(23):2879–2881CrossRef
19.
Chen S-N, Lian I, Hwang Y-C et al (2015) Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina 35(4):667–674CrossRef
20.
Castellanos MAM, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H (2013) Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 97(7):816–819CrossRef
21.
Sukgen EA, Koçluk Y (2017) The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol 80(1):30–34CrossRef
Metadata
Title
Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity
Authors
Amir Eftekhari Milani
Narges Hassanpoor
Mohammadreza Mousavi Mirkala
Arash Taheri
Ali Golizade
Mohamad Reza Niyousha
Publication date
01-02-2020
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 2/2020
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-019-01208-3

Other articles of this Issue 2/2020

International Ophthalmology 2/2020 Go to the issue

Original Paper

A small incision technique for repairing involutional lower eyelid entropion

Original Paper

Visual acuity and defocus curves with six multifocal intraocular lenses

Original Paper

Sagittal height differences of disposable soft contact lenses

Original Paper

Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy

Review

Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies

Review

Ocular manifestations of rheumatic diseases